JP2003530307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530307A5 JP2003530307A5 JP2001508378A JP2001508378A JP2003530307A5 JP 2003530307 A5 JP2003530307 A5 JP 2003530307A5 JP 2001508378 A JP2001508378 A JP 2001508378A JP 2001508378 A JP2001508378 A JP 2001508378A JP 2003530307 A5 JP2003530307 A5 JP 2003530307A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- adenovirus
- gene
- vaccine
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013598 vector Substances 0.000 description 32
- 241000701161 unidentified adenovirus Species 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 101710177291 Gag polyprotein Proteins 0.000 description 8
- 101710125418 Major capsid protein Proteins 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 229940021704 adenovirus vaccine Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 101150029662 E1 gene Proteins 0.000 description 5
- 230000002950 deficient Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 3
- 101150005585 E3 gene Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 108010057360 Adenovirus E1 Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14263199P | 1999-07-06 | 1999-07-06 | |
| US60/142,631 | 1999-07-06 | ||
| US14898199P | 1999-08-13 | 1999-08-13 | |
| US60/148,981 | 1999-08-13 | ||
| PCT/US2000/018332 WO2001002607A1 (en) | 1999-07-06 | 2000-07-03 | Adenovirus carrying gag gene hiv vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530307A JP2003530307A (ja) | 2003-10-14 |
| JP2003530307A5 true JP2003530307A5 (enExample) | 2006-12-07 |
Family
ID=26840267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001508378A Withdrawn JP2003530307A (ja) | 1999-07-06 | 2000-07-03 | ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6787351B2 (enExample) |
| EP (1) | EP1200622A4 (enExample) |
| JP (1) | JP2003530307A (enExample) |
| CA (1) | CA2378539A1 (enExample) |
| WO (1) | WO2001002607A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020088014A1 (en) * | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| EP1141314A2 (en) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| US20020106798A1 (en) | 2000-03-02 | 2002-08-08 | Robinson Harriet L. | DNA expression vectors and methods of use |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| US7754201B2 (en) * | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
| US20020155127A1 (en) * | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| CA2415347A1 (en) * | 2000-07-14 | 2002-01-24 | University Of Saskatchewan | Adenovirus vectors comprising introns |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| CN1247785C (zh) | 2000-10-13 | 2006-03-29 | 希龙公司 | 巨细胞病毒内含子a片段 |
| CN100446812C (zh) | 2001-03-08 | 2008-12-31 | 美国国有健康与人类服务部 | 表达修饰的hiv包膜、gag和pol基因的mva |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| JP4475561B2 (ja) | 2001-10-11 | 2010-06-09 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃ型肝炎ウイルスワクチン |
| MXPA04004876A (es) | 2001-11-21 | 2004-07-30 | Univ Pennsylvania | Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso. |
| GB2396814B (en) | 2001-11-30 | 2006-07-19 | Isis Innovation | Fowlpox vector |
| WO2003077859A2 (en) * | 2002-03-13 | 2003-09-25 | Merck & Co., Inc. | Method of inducing an enhanced immune response against hiv |
| ATE386824T1 (de) | 2002-03-29 | 2008-03-15 | Merck & Co Inc | Verfahren zur virusproduktion |
| EP1506287B1 (en) | 2002-05-14 | 2007-04-25 | Merck & Co., Inc. | Methods of adenovirus purification |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| EP1573012B1 (en) | 2002-12-17 | 2011-11-30 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| EP1663114A2 (en) * | 2003-09-18 | 2006-06-07 | Merck & Co., Inc. | Therapeutic immunization of hiv-infected individuals |
| WO2005110492A2 (en) * | 2004-04-12 | 2005-11-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of using adenoviral vectors to induce an immune response |
| US7741099B2 (en) | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
| WO2007050095A2 (en) | 2004-11-19 | 2007-05-03 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| WO2006111387A2 (en) * | 2005-04-22 | 2006-10-26 | Lonza Biologics Plc. | Mammalian expression vector comprising the mcmv promoter and first intron of hcmv major immediate early gene |
| CA2634377A1 (en) * | 2005-12-21 | 2007-06-28 | Glaxo Group Limited | Method of eliciting immune response |
| CA2653256C (en) * | 2006-05-25 | 2018-08-28 | Institute For Advanced Study | Methods for identifying sequence motifs, and applications thereof |
| US9422342B2 (en) | 2006-07-13 | 2016-08-23 | Institute Of Advanced Study | Recoding method that removes inhibitory sequences and improves HIV gene expression |
| US8926993B2 (en) | 2006-07-17 | 2015-01-06 | Aduro Biotech | Methods and compositions using Listeria for enhancing immunogenicity by prime boost |
| GB0706914D0 (en) | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| WO2009026183A1 (en) * | 2007-08-17 | 2009-02-26 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Use of chimeric hiv/siv gag proteins to optimize vaccine-induced t cell responses against hiv gag |
| JP5775451B2 (ja) | 2008-06-19 | 2015-09-09 | バリエーション バイオテクノロジーズ インコーポレイティド | インフルエンザを処置するための組成物および方法 |
| EP2213299B1 (fr) | 2009-01-29 | 2015-09-09 | Michel Vandevelde | Composition vaccinale à base de virus exhibant une protéine à motif(s) en doigt de zinc, son procédé de préparation et son utilisation |
| US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| MX2012000372A (es) | 2009-07-06 | 2012-02-28 | Variation Biotechnologies Inc | Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas. |
| BRPI0914507A2 (pt) * | 2009-12-23 | 2012-04-10 | Fundacao Oswaldo Cruz | vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela |
| CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
| US10736844B2 (en) | 2011-01-13 | 2020-08-11 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| US10183069B2 (en) * | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| ES2606511T3 (es) | 2011-04-06 | 2017-03-24 | Biovaxim Limited | Composiciones farmacéuticas para prevenir y/o tratar una enfermedad por VIH en seres humanos |
| CA2894442C (en) | 2012-01-12 | 2020-01-21 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| EP4008354A1 (en) | 2012-01-27 | 2022-06-08 | Variation Biotechnologies Inc. | Methods and compositions for therapeutic agents |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| KR102044051B1 (ko) | 2012-03-12 | 2019-11-12 | 얀센 백신스 앤드 프리벤션 비.브이. | 터미널 말단이 변경된 재조합 아데노바이러스의 배치 |
| KR101466874B1 (ko) * | 2012-05-11 | 2014-12-03 | 가톨릭대학교 산학협력단 | 자가면역 질환의 예방과 치료를 위한 ｉｌ-６ 수용체에 대한 항체를 발현하는 미니서클 |
| KR101466875B1 (ko) * | 2012-05-11 | 2014-12-03 | 가톨릭대학교 산학협력단 | 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료 |
| CA2891349C (en) | 2012-11-16 | 2023-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| EP3271729B1 (en) | 2015-03-18 | 2020-09-23 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
| AU2016249798B2 (en) | 2015-04-14 | 2022-05-26 | Janssen Vaccines And Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| US11001858B2 (en) | 2016-06-20 | 2021-05-11 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| MX421606B (es) | 2017-10-31 | 2025-03-14 | Janssen Vaccines & Prevention Bv | Vectores adenovirales y usos de estos |
| SG11202003399TA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof |
| WO2019086450A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| MX2020004488A (es) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus y usos de estos. |
| WO2019118480A1 (en) | 2017-12-11 | 2019-06-20 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
| US20210317192A9 (en) | 2019-05-29 | 2021-10-14 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
| CA3156471A1 (en) | 2019-10-03 | 2021-04-08 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| US11571672B2 (en) | 2019-11-25 | 2023-02-07 | Saudi Arabian Oil Company | Method of providing catalysts for a fluidized bed reactor |
| CN111949888B (zh) * | 2020-09-02 | 2023-10-10 | 度小满科技(北京)有限公司 | 一种数据推荐方法及装置 |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| CA2003383A1 (en) * | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Synthetic dna derived recombinant hiv antigens |
| ATE243755T1 (de) | 1992-08-07 | 2003-07-15 | Wyeth Corp | Rekombinente adenoviren-impfstoffe |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| DK0638316T3 (da) | 1993-08-11 | 2003-09-22 | Wyeth Corp | Rekombinante adenovirusvacciner |
| AU711269B2 (en) | 1994-08-16 | 1999-10-07 | Crucell Holland B.V. | Recombinant vectors derived from adenovirus for use in gene therapy |
| ES2176360T3 (es) | 1994-12-30 | 2002-12-01 | Chiron Corp | Combinacion de vehiculos de administracion de genes. |
| WO1996039178A1 (en) | 1995-06-05 | 1996-12-12 | The Wistar Institute Of Anatomy And Biology | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| US6019978A (en) | 1995-06-05 | 2000-02-01 | The Wistar Institute Of Anatomy And Biology | Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
| US5672508A (en) * | 1996-01-23 | 1997-09-30 | Mitotix, Inc. | Inhibitors of cell-cycle progression, and uses related thereto |
| ATE309366T1 (de) | 1996-02-22 | 2005-11-15 | Merck & Co Inc | Synthetische hiv-gene |
| CA2252406A1 (en) | 1996-04-22 | 1997-10-30 | Nicholas P. Restifo | Heterologous boosting immunizations |
| AU728422B2 (en) | 1996-06-21 | 2001-01-11 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
| EE9900343A (et) | 1997-02-07 | 2000-02-15 | Merck & Co., Inc. | Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| EP1199089A1 (en) | 1999-06-30 | 2002-04-24 | Javier Garrigues Mateo | Off side detection system |
| GB9922361D0 (en) | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| AU782193B2 (en) | 1999-12-17 | 2005-07-07 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef |
| WO2001045748A1 (en) | 1999-12-22 | 2001-06-28 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
-
2000
- 2000-07-03 JP JP2001508378A patent/JP2003530307A/ja not_active Withdrawn
- 2000-07-03 WO PCT/US2000/018332 patent/WO2001002607A1/en not_active Ceased
- 2000-07-03 CA CA002378539A patent/CA2378539A1/en not_active Abandoned
- 2000-07-03 EP EP00945133A patent/EP1200622A4/en not_active Withdrawn
-
2001
- 2001-03-27 US US09/818,443 patent/US6787351B2/en not_active Expired - Fee Related
-
2003
- 2003-06-13 US US10/461,030 patent/US20030228329A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7053728B2 (ja) | 組換えアデノウイルスおよびその使用 | |
| US11104916B2 (en) | Compositions and methods for alphavirus vaccination | |
| US12285481B2 (en) | Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein | |
| US20220062409A1 (en) | Heterologous prime boost vaccine compositions and methods | |
| TWI828168B (zh) | 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途 | |
| JP2004508064A5 (enExample) | ||
| JP2008110963A (ja) | 調節剤の粘膜投与による感染している哺乳類における免疫応答の調節方法 | |
| JP2002533124A5 (enExample) | ||
| EP1825863A1 (en) | Recombinant porcine adenovirus vector | |
| JP2005505286A5 (enExample) | ||
| KR20230050328A (ko) | Hbv에 대한 rna 레플리콘 백신 | |
| JP2004501650A5 (enExample) | ||
| CN111363726A (zh) | 表达干扰素的溶瘤病毒及其应用 | |
| FR2712602A1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| BR112020012273A2 (pt) | métodos e composições para induzir uma resposta imune contra o vírus da hepatite b (hbv) | |
| CN100471957C (zh) | 用于免疫治疗的腺病毒载体 | |
| Kon et al. | Naked plasmid‐mediated gene transfer to skeletal muscle ameliorates diabetes mellitus | |
| CA2461579A1 (en) | Porcine adenovirus e1 region | |
| Chengalvala et al. | Adenovirus vectors for gene expression | |
| KR100686356B1 (ko) | 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제 | |
| JP2008521384A (ja) | コロナウィルス様粒子をコードする発現ベクター | |
| WO2004033696A2 (fr) | Vecteurs adenoviraux recombinants et leurs applications | |
| CN1094974C (zh) | 表达人白细胞介素12的重组腺病毒及其制法和用途 | |
| JP2005519959A (ja) | Ｈｉｖに対する強化された免疫応答を誘導する方法 | |
| Pergolizzi et al. | Protective immunity against α-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant |